(NasdaqGM:CRMD), BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) — CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced an addition to its executive leadership team and updates to its Board of Directors. CorMedix CEO Joseph Todisco has signed an extended employment contract, […]

NORTH LITTLE ROCK, Ark., Jan. 08, 2026 (GLOBE NEWSWIRE) — First Orion, a leading provider of branded calling solutions, today announced a new go-to-market collaboration with Deutsche Telekom to introduce branded calling services to enterprise customers across Germany. Through this initiative, Deutsche Telekom will offer First Orion's branded calling solution to its business customers, enabling

NORTH LITTLE ROCK, Ark., Jan. 08, 2026 (GLOBE NEWSWIRE) — First Orion, a leading provider of branded calling solutions, today announced a new go-to-market collaboration with Deutsche Telekom to introduce branded calling services to enterprise customers across Germany. Through this initiative, Deutsche Telekom will offer First Orion's branded calling solution to its business customers, enabling

First Orion Partners with Deutsche Telekom to Launch Branded Calling to Combat Call Fraud in Germany GlobeNewswire January 08, 2026 NORTH LITTLE ROCK, Ark., Jan. 08, 2026 (GLOBE NEWSWIRE) — First Orion, a leading provider of branded calling solutions, today announced a new go-to-market collaboration with Deutsche Telekom to introduce branded calling services to enterprise

CorMedix Therapeutics Announces Leadership and Board Updates GlobeNewswire January 08, 2026 BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) — CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced an addition to its executive leadership team and updates to its Board of Directors.

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation GlobeNewswire January 08, 2026 InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa (HS) To broaden signal-finding activities for izicopan in additional I&I (inflammation and immunology) indications, InflaRx intends to

Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa GlobeNewswire January 08, 2026 GAITHERSBURG, Md. and PARIS and ADDIS ABABA, Ethiopia, Jan. 08, 2026 (GLOBE NEWSWIRE) — Today Emergent BioSolutions (NYSE: EBS) announced a collaboration agreement with PANTHER to provide additional financial support to continue progressing

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib GlobeNewswire January 08, 2026 Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been previously treated with anti-PD-1/PD-L1 therapy and platinum-based chemotherapy First Breakthrough Therapy Designation for an investigational

First Orion Partners with Deutsche Telekom to Launch Branded Calling to Combat Call Fraud in Germany GlobeNewswire January 08, 2026 NORTH LITTLE ROCK, Ark., Jan. 08, 2026 (GLOBE NEWSWIRE) — First Orion, a leading provider of branded calling solutions, today announced a new go-to-market collaboration with Deutsche Telekom to introduce branded calling services to enterprise

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies GlobeNewswire January 08, 2026 CORAL GABLES, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat